Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Conditions
- Anaplastic Large Cell Lymphoma
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Intraocular Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Small Intestine Lymphoma
- Splenic Marginal Zone Lymphoma
- Testicular Lymphoma
- Waldenstrom Macroglobulinemia
Interventions
- BIOLOGICAL: DI-Leu16-IL2 immunocytokine
- BIOLOGICAL: rituximab
- OTHER: flow cytometry
- OTHER: immunohistochemistry staining method
- OTHER: pharmacological study
- OTHER: laboratory biomarker analysis
- OTHER: enzyme-linked immunosorbent assay
- GENETIC: reverse transcriptase-polymerase chain reaction
Sponsor
City of Hope Medical Center
Collaborators